Australia markets closed
  • ALL ORDS

    6,720.40
    -26.10 (-0.39%)
     
  • ASX 200

    6,539.90
    -28.20 (-0.43%)
     
  • AUD/USD

    0.6818
    -0.0087 (-1.25%)
     
  • OIL

    108.46
    +2.70 (+2.55%)
     
  • GOLD

    1,812.90
    +5.60 (+0.31%)
     
  • BTC-AUD

    28,273.55
    +98.16 (+0.35%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • AUD/EUR

    0.6533
    -0.0048 (-0.73%)
     
  • AUD/NZD

    1.0973
    -0.0077 (-0.70%)
     
  • NZX 50

    10,753.16
    -115.54 (-1.06%)
     
  • NASDAQ

    11,585.68
    +81.96 (+0.71%)
     
  • FTSE

    7,168.65
    -0.63 (-0.01%)
     
  • Dow Jones

    31,097.26
    +321.83 (+1.05%)
     
  • DAX

    12,813.03
    +29.26 (+0.23%)
     
  • Hang Seng

    21,859.79
    -137.10 (-0.62%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     

Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Koninklijke Philips N.V. PHG reported first-quarter 2022 adjusted earnings of €0.15 per share, down 46.4% year over year.

Sales increased 2% on a year-over-year basis to €3.92 billion. Comparable sales (includes adjustments for consolidation charges & currency effects) decreased 4% year over year, primarily due to headwinds caused by global supply chain challenges and consequences of the Respironics field action.

Comparable sales in the Personal Health businesses witnessed high-single-digit increase on a year-over-year basis. This was fully offset by a double-digit decline in the Connected Care businesses and low-single-digit decline in the Diagnosis & Treatment businesses.

Philips’ comparable order intake grew 5% year over year in the reported quarter. Diagnosis & Treatment businesses witnessed high-single-digit growth, while the Connected Care business reported flat comparable order intake.

Sales decreased 3% on a comparable basis in growth geographies. Sales in mature geographies were down 4% year over year on a comparable basis.

Koninklijke Philips N.V. Price, Consensus and EPS Surprise

Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. Price, Consensus and EPS Surprise

Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote

Philips’ shares were down more than 11% following first-quarter 2022 results. Markedly, Philips’ shares have dropped 17.7% to date compared with the Zacks Medical-Products industry’s decline of 12.7%.

Segmental Update

Diagnosis & Treatment revenues increased 3% from the year-ago quarter to €1.91 billion. Comparable sales declined 2% year over year.

Image-Guided Therapy witnessed high-single-digit growth in the reported quarter. However, Ultrasound and Diagnostic Imaging revenues declined due to supply chain shortages and tough year-over-year comparisons.

Connected Care business revenues declined 14% year over year to €993 million. Comparable sales decreased 21%, primarily due to consequences of the Respironics field action and the impact of supply chain headwinds.

Personal Health sales increased 13% year over year to €838 million. Comparable sales were up 8%, with double-digit growth in Oral Healthcare and Mother & Child Care, while remaining flat in Personal Care.

Other segment sales €176 million, up €100 million on a year-over-year basis.

Operating Details

Gross margin contracted 30 basis points (bps) on a year-over-year basis to 38.6% in the reported quarter.

General & administrative expenses, as percentage of sales, decreased 60 bps on a year-over-year basis to 4%. However, selling expenses increased 140 bps to 27.2%. Research & development expenses also increased 160 bps to 12.6%.

In the reported quarter, procurement cost savings totaled €97 million. In response to the inflationary headwinds, Philips is implementing additional cost-saving measures of €150-200 million for 2022.

Restructuring, acquisition-related and other charges amounted to €350 million compared with €301 million in the year-ago quarter. The reported quarter’s figure includes €65 million for the Respironics field action provision, a €100-million provision related to potential higher execution costs of the field action program and €50 million for running remediation costs in Respironics.

Philips’ adjusted earnings before interest, taxes and amortization (“EBITA”) — the company’s preferred measure of operational performance — were negative €107 million against positive EBITA of €61 million.

Diagnosis & Treatment EBITA margins contracted 280 bps on a year-over-year basis to 5.9%. Connected Care adjusted EBITA margin was 0.4% compared with 12.9% in the year-ago quarter.

Personal Health’s adjusted EBITA margins expanded 130 bps on a year-over-year basis to 15.3%.

Balance Sheet

As of Mar 31, 2022, Philips’ cash and cash equivalents were €1.44 billion and total debt was €7 billion. This compares with cash and cash equivalents of €2.30 billion and total debt of €6.98 billion as of Dec 31, 2021.

Guidance

Philips expects 2022 comparable sales growth between 3% and 5%. First-half sales growth is expected to decline in the mid-single-digit range, while in second-half 2022 it is anticipated to witness high-single-digit growth.

Zacks Rank and Stocks to Consider

Phillips currently has a Zacks Rank #5 (Strong Sell).

Lantheus Holdings LNTH, Owens & Minor OMI and Maravai Life Sciences MRVI are better-ranked stocks worth considering in the same industry. All the three stocks flaunt a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Lantheus, Owens & Minor and Maravai are expected to report their quarterly results on Apr 29, May 3 and May 5, respectively.

On a year-to-date basis, Lantheus has returned 101.9%. However, shares of Owens & Minor and Maravai are down 8.8% and 21.3%, respectively.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report

Owens & Minor, Inc. (OMI) : Free Stock Analysis Report

Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report

Maravai LifeSciences Holdings, Inc. (MRVI) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting